Search hospitals > Virginia > Charlottesville
Charlottesville Medical Research
Claim this profileCharlottesville, Virginia 22911
Global Leader in Migraine
Global Leader in Osteoarthritis
Conducts research for Crohn's Disease
Conducts research for Obesity
Conducts research for Flu
115 reported clinical trials
2 medical researchers
Summary
Charlottesville Medical Research is a medical facility located in Charlottesville, Virginia. This center is recognized for care of Migraine, Osteoarthritis, Crohn's Disease, Obesity, Flu and other specialties. Charlottesville Medical Research is involved with conducting 115 clinical trials across 86 conditions. There are 2 research doctors associated with this hospital, such as James Clark and Daniel Pambianco, MD.Top PIs
James ClarkCharlottesville Medical Research3 years of reported clinical research
Studies Diabetes
Studies Type 2 Diabetes
9 reported clinical trials
13 drugs studied
Daniel Pambianco, MDCharlottesville Medical Research4 years of reported clinical research
Studies Colorectal Cancer
Studies Peptic Esophagitis
2 reported clinical trials
3 drugs studied
Clinical Trials running at Charlottesville Medical Research
Migraine
Type 2 Diabetes
Ulcerative Colitis
Obesity
Flu
High Cholesterol
Inflammatory Bowel Disease
Ulcer
Hardening of the Arteries
Urinary Tract Infection
Ubrogepant
for Migraine
A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. Menstrual migraine (MM) is defined as migraine attacks that occur within the perimenstrual period (PMP) in at least 2 out of 3 menstrual cycles. The PMP is from 2 days before the onset of menstrual bleeding to 2 days after. This study will assess how safe and effective ubrogepant is in treating menstrual migraine. Adverse Events and change in disease activity will be assessed. Ubrogepant is an investigational drug being developed for short-term prevention of menstrual migraine. Participants will be randomly assigned to one of the 2 groups to receive either ubrogepant or placebo. Around 450 adult female participants with menstrual migraine will be enrolled in approximately 85 sites in the United States and Puerto Rico. Participants will receive oral ubrogepant tablets once daily for 7 consecutive days starting 3 days prior to estimated onset of menses per cycle for 3 PMPs during double-blind period (16 weeks). Eligible participants may continue to receive oral ubrogepant tablets once daily for 7 consecutive days per cycle starting 3 days prior to estimated onset of menses during open-label extension period (52 weeks). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will collect data daily in electronic diaries and attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Recruiting1 award Phase 33 criteria
BOTOX Injections
for Migraine
This study is evaluating whether a treatment for migraine can prevent migraine attacks in adults with episodic migraine.
Recruiting1 award Phase 34 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Charlottesville Medical Research?
Charlottesville Medical Research is a medical facility located in Charlottesville, Virginia. This center is recognized for care of Migraine, Osteoarthritis, Crohn's Disease, Obesity, Flu and other specialties. Charlottesville Medical Research is involved with conducting 115 clinical trials across 86 conditions. There are 2 research doctors associated with this hospital, such as James Clark and Daniel Pambianco, MD.